Gregg McConnell

Corporate Officer/Principal at TCR2 THERAPEUTICS INC.

Health Technology

Consumer Services

Profile

Gregg McConnell is currently the Head of Business Development at TCR2 Therapeutics, Inc. He previously worked as the Senior Director of Worldwide Business Development at Pfizer Inc. and as the Vice President and Head of Business Development at BlueRock Therapeutics Canada ULC.
He received an undergraduate degree from Cornell University, an MBA from The Wharton School of the University of Pennsylvania, and a graduate degree from the Zanvyl Krieger School of Arts & Sciences.

Gregg McConnell active positions

Companies	Position	Start
TCR2 THERAPEUTICS INC.	Corporate Officer/Principal	26/05/2020

All active positions of Gregg McConnell

Former positions of Gregg McConnell

Companies	Position	End
PFIZER, INC.	Corporate Officer/Principal	-
BlueRock Therapeutics Canada ULC BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada.	Corporate Officer/Principal	-

See the detail of Gregg McConnell's experience

Training of Gregg McConnell

The Wharton School of the University of Pennsylvania	Masters Business Admin
Cornell University	Undergraduate Degree
Zanvyl Krieger School of Arts & Sciences	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Gregg McConnell's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
PFIZER, INC.	Health Technology

Private companies	2
TCR2 Therapeutics, Inc. TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.	Health Technology
BlueRock Therapeutics Canada ULC BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada.	Health Technology